Cost-effectiveness of [¹¹C]Choline PET/CT as first-line imaging in primary hyperparathyroidism
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-025-07746-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von H M Schouw und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. h.m.s…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Choline, Hyperparathyroidism, Primary. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
We performed a cost-utility analysis, using prospectively gathered trial data, comparing two imaging strategies for localizing parathyroid adenomas in primary hyperparathyroidism (pHPT) to determine the most cost-effective approach. Additionally, we provide customizable open-source R-script enabling other centres to identify their optimal imaging strategy based on local diagnostic accuracy and cost data.
Methods
An evaluation of the diagnostic accuracy was performed for five imaging modalities: first-line cervical ultrasound (cUS) and [ 99m Tc]Tc-methoxy isobutyl isonitrile-single-photon-emission-computed- tomography/computed-tomography (MIBI SPECT/CT), and second-line [¹¹C]choline positron-emitting-tomography/CT (PET/CT), [¹¹C]methionine PET/CT, and 4 dimensional (4D)-CT. A decision-tree-model, constructed in R-studio, compared two diagnostic pathways: (1) The comparator pathway: a stepwise approach starting with cUS and MIBI SPECT/CT escalating to one of three second-line imaging modalities if needed, and (2) use of only one second-line imaging. Costs and quality-adjusted life years (QALYs) were evaluated across pathways, and cost-utility ratios (€/QALY) were calculated for a centre specific perspective with a 24-year time horizon based on life expectancy. In addition, to test the joint parameter uncertainty of the model, a probabilistic Monte-Carlo analysis was performed. One- and two-way sensitivity analyses were conducted to assess model robustness. Results [¹¹C]choline PET/CT had a total costs of €10,394 and a QALY gain of 16.66. In contrast, the current standard, cUS + MIBI SPECT/CT with, when necessary, second-line imaging, costs €10,907 and yields 16.63 QALYs. The incremental cost-utility ratio (ICUR) for [¹¹C]choline PET/CT was -€18,846/QALY, indicating dominance with lower cost and greater effectiveness. Sensitivity analyses showed that cost-effectiveness was most sensitive to variations in costs of [¹¹C]choline PET/CT.
Conclusion
This centre-specific model supports first-line [¹¹C]choline PET/CT as a cost-effective first-line strategy for localization of parathyroid adenomas, depending on [¹¹C]choline PET/CT costs. Additionally, the provided cost-utility model, enables other centres to determine their optimal imaging strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. h.m.schouw@umcg.nl.
- Department of Surgery, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. h.m.schouw@umcg.nl.
- Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden. h.m.schouw@umcg.nl.
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre of Groningen, Groningen, The Netherlands.
- Department of Surgery, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
ORCID-Profile: H M Schouw
Zitieren
APA
Schouw, H. M., Melis, J., Lutterop, J. W., Boersma, H. H., Noltes, M. E., van der Hilst, C. S., Bonnema, M. I., Appelman, A. P. A., Zandee, W. T., Kruijff, S., Vermeulen, K. M., & Brouwers, A. H. (2026). Cost-effectiveness of [¹¹C]Choline PET/CT as first-line imaging in primary hyperparathyroidism. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07746-6
Vancouver
Schouw HM, Melis J, Lutterop JW, Boersma HH, Noltes ME, van der Hilst CS, et al. Cost-effectiveness of [¹¹C]Choline PET/CT as first-line imaging in primary hyperparathyroidism. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07746-6
BibTeX
@article{Schouw2026,
author = {Schouw, H M and Melis, J and Lutterop, J W and Boersma, H H and Noltes, M E and van der Hilst, C S and Bonnema, M I and Appelman, A P A and Zandee, W T and Kruijff, S and Vermeulen, K M and Brouwers, A H},
title = {Cost-effectiveness of [¹¹C]Choline PET/CT as first-line imaging in primary hyperparathyroidism},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-025-07746-6}
}
EUVIMED